HERBERT LABS' NAFTIN TOPICAL ANTI-FUNGAL CREAM SCHEDULED FOR JUNE LAUNCH
Executive Summary
Herbert Labs is planning a June market introduction for its recently approved topical anti-fungal Naftin (naftifine), the SmithKline/Allergan subsidiary told "The Pink Sheet." The cream product cleared FDA on Feb. 29 as a 1C drug (new molecular entity with little or no therapeutic gain). Herbert filed its NDA in March 1986. Despite indications from FDA that the approval momentum from the end of 1987 would continue into the first quarter of 1988, Naftin was apparently the only new chemical entity approved during the past three months. FDA also recently approved McNeil's anti-motility agent loperamide for use as an OTC product ("The Pink Sheet" March 14, p. 15). "Naftin Cream is indicated for the topical treatment of tinea cruris and tinea corporis," the product labeling states. Naftin will be supplied in 2, 15 and 30 gram tubes. The product will be priced to wholesalers at $ 6.48 per 15 g tube and $ 11.05 per 30 g tube. SmithKline said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth